Bio-Techne Corp
TECH
View Detailed Chart
66.780USD
+0.920+1.40%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
10.41BMarket Cap
127.68P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.40%
5 Days
+4.20%
1 Month
+2.30%
6 Months
+33.91%
Year to Date
+13.55%
1 Year
-10.97%
View Detailed Chart
TradingKey Stock Score of Bio-Techne Corp
Currency: USD Updated: 2026-02-06Key Insights
Bio-Techne Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 75.20.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bio-Techne Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Bio-Techne Corp Highlights
StrengthsRisks
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.
Overvalued
The company’s latest PE is 127.68, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 172.52M shares, increasing 1.83% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 93.35K shares of this stock.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
75.197
Target Price
+14.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bio-Techne Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bio-Techne Corp Info
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Ticker SymbolTECH
CompanyBio-Techne Corp
CEOKelderman (Kim)
Websitehttps://www.bio-techne.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
67775.240
-2194.890 (-3.14%)
282.580
+22.390 (+8.61%)
2003.920
-47.810 (-2.33%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
